Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.60 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.59 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21661360 | 1.00 | CHRNB2 (0.60) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL30914545 | 0.91 | GNAI3 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL4635163 | 0.90 | GNAI3 (0.69) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL13285080 | 0.90 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL1438745 | 0.89 | GNAI3 (0.73) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12574191 | 0.87 | GNAI3 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL3935665 | 0.87 | GNAI3 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL22179378 | 0.87 | GNAI3 (0.80) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL22178856 | 0.87 | GNAI3 (0.80) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL22179122 | 0.87 | GNAI3 (0.80) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1427326-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Sugen, Inc. (US) | 2004-06-16 | — | — | EP | claimed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | claimed |
| US-10632171-B2 | Melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190216887-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-10179804-B2 | Melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| EP-2440227-B1 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20160318977-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES INC (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318977-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES INC (US) | 2016-11-03 | — | — | US | disclosed |
| US-9458201-B2 | Melanocortin receptor-specific heptapeptides | PALATIN TECHNOLOGIES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20120178701-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011088045-A1 | AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE | AMBIT BIOSCIENCES CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010144344-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-0265230-B1 | SUBSTITUTED-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACIDS, DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS, AND PROCESSES FOR PRODUCING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0265230-A1 | Substituted-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids, derivatives thereof, pharmaceutical compositions comprising the compounds, and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179804-B2 | Melanocortin receptor-specific peptides | MC1R, MC3R, MC5R | CHRNB2 278/4885CHRNB4 392/4885CHRNA3 239/4885 |
| US-20190216887-A1 | Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC4R | CHRNB2 194/4885CHRNB4 280/4885CHRNA3 211/4885 |
| US-20160318977-A1 | Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC5R | CHRNB2 278/4885CHRNB4 392/4885CHRNA3 239/4885 |
| US-10632171-B2 | Melanocortin receptor-specific peptides | MC1R, MC3R, MC4R | CHRNB2 194/4885CHRNB4 280/4885CHRNA3 211/4885 |
| US-20120178701-A1 | Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC5R | CHRNB2 278/4885CHRNB4 392/4885CHRNA3 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.